MicrobioSeq Announces the Launch of the Phage Whole-Genome Sequencing Service

MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The company has launched the Phage Whole-Genome Sequencing to help discover biomarkers and develop non-antibiotic treatment methods.

Phages are a group of viruses that invade bacteria, some of which can cause lysis of the host bacteria and some of which can confer additional biological properties to the genetic material of the host bacteria. Phages attack bacteria and are strictly host-specific, depending on the molecular structure and complementarity of the phage and the surface receptors of the recipient bacteria.

Phages are the most common and widely distributed viruses and are usually found in abundance in areas filled with bacterial communities, such as soil and the gastrointestinal tract. Phages are not to be neglected for study when studying microecology. These studies offer noteworthy industry opportunities.

“CD Genomics uses next-generation sequencing and long-read sequencing technologies (mainly Illumina HiSeq, Nanopore, and PacBio SMRT sequencing) to provide virus/phage sequencing services and help in-depth studies of structural genomics and comparative genomics. Based on the virus genome sequencing platform, we provide resequencing and de novo sequencing strategies to construct draft or complete virus/phage genomes,” commented the chief scientist of CD Genomics.

Based on proven second-generation sequencing and third-generation whole-genome sequencing platforms, CD Genomics provides comprehensive and reliable phage whole-genome de novo sequencing, resequencing, and genetic analysis services. These sequencing technologies are also tools for understanding biochemical interactions between prokaryotes and phages and have been widely used in the food industry and medical research. For example, multiple drug resistance (MDR) has risen dramatically, and phage therapy may be an effective way to treat bacterial infections.

“Our microbial whole-genome sequencing platform utilizes cutting-edge high-throughput sequencing technologies to study the whole genomes of novel or known microorganisms in an efficient and cost-effective manner. Our experienced scientists will select the most appropriate sequencing strategy and data analysis process based on your samples and research objectives. The microbial whole genome sequencing platform is an automated and intelligent platform utilizing Illumina HiSeq sequencing, PacBio SMRT sequencing, and/or Nanopore sequencing. It resolves whole genome assemblies, especially for repeat-dense and GC-rich genomes, as well as plasmids. ” he further added.

About the MicrobioSeq Division of CD Genomics

MicrobioSeq is the microbial genomics division of CD Genomics, which is a genomics service company with a good reputation for providing reliable microbial sampling products, microbial testing services, microbial genomics services, and integrated bioinformatics services.

Contact

Address: Shirley, NY 11967, USA

Email: contact@cd-genomics.com